Completed PHASE1 INTERVENTIONAL 4-arm NCT00629759

A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma

Phase 1 Clinical Study for Evaluating the Safety and Efficacy of a Transdermal Injection of JX-594 (Thymidine Kinase (-)/GM-CSF(+) Vaccinia Virus) Within the Tumor of Patients With Hepatic Carcinoma

Sponsor: Green Cross Corporation

Conditions Neoplasms, Liver

Interventions JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)

Updated 6 times since 2017 Last updated: Jan 3, 2013 Started: Jan 31, 2006 Primary completion: Jul 31, 2007 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00629759, this PHASE1 trial focuses on Neoplasms, Liver and remains completed. Sponsored by Green Cross Corporation, it has been updated 6 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Green Cross Corporation
Jennerex Biotherapeutics

Data source: Jennerex Biotherapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Busan, South Korea